Indeed, numerous studies have indicated that alternative splicing occurs frequently in cancer cells, and a plethora of cancer-specific splice variants have been reported [26–28]; and some of them are considered to be candidate cancer biomarkers, such as CD44 [28] and the Wilms tumor (WT1) genes [29]. This evidence concerns the gene WT1 and neoplasm.